Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome® in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia

NCT00451711 is registered in ClinicalTrials.gov with Bayside Health as lead sponsor.

NCT NCT00451711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00451711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome® in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia
Lead sponsor
Bayside Health
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2007
Completion date
October 31, 2014
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia